Literature DB >> 25765764

LRIG1 extracellular domain: structure and function analysis.

Yibin Xu1, Priscilla Soo2, Francesca Walker3, Hui Hua Zhang4, Nicholas Redpath5, Chin Wee Tan3, Nicos A Nicola5, Timothy E Adams6, Thomas P Garrett3, Jian-Guo Zhang7, Antony W Burgess8.   

Abstract

We have expressed and purified three soluble fragments of the human LRIG1-ECD (extracellular domain): the LRIG1-LRR (leucine-rich repeat) domain, the LRIG1-3Ig (immunoglobulin-like) domain, and the LRIG1-LRR-1Ig fragment using baculovirus vectors in insect cells. The two LRIG1 domains crystallised so that we have been able to determine the three-dimensional structures at 2.3Å resolution. We developed a three-dimensional structure for the LRIG1-ECD using homology modelling based on the LINGO-1 structure. The LRIG1-LRR domain and the LRIG1-LRR-1Ig fragment are monomers in solution, whereas the LRIG1-3Ig domain appears to be dimeric. We could not detect any binding of the LRIG1 domains or the LRIG1-LRR-1Ig fragment to the EGF receptor (EGFR), either in solution using biosensor analysis or when the EGFR was expressed on the cell surface. The FLAG-tagged LRIG1-LRR-1Ig fragment binds weakly to colon cancer cells regardless of the presence of EGFRs. Similarly, neither the soluble LRIG1-LRR nor the LRIG1-3Ig domains nor the full-length LRIG1 co-expressed in HEK293 cells inhibited ligand-stimulated activation of cell-surface EGFR.
Copyright © 2015. Published by Elsevier Ltd.

Entities:  

Keywords:  EGFR inhibition; LINGO-1; leucine-rich repeat domain; stem cell marker

Mesh:

Substances:

Year:  2015        PMID: 25765764     DOI: 10.1016/j.jmb.2015.03.001

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  7 in total

Review 1.  HYPOTHESIS: Do LRIG Proteins Regulate Stem Cell Quiescence by Promoting BMP Signaling?

Authors:  Carl Herdenberg; Håkan Hedman
Journal:  Stem Cell Rev Rep       Date:  2022-08-15       Impact factor: 6.692

2.  LRIG1 is a conserved EGFR regulator involved in melanoma development, survival and treatment resistance.

Authors:  Ola Billing; Ylva Holmgren; Daniel Nosek; Håkan Hedman; Oskar Hemmingsson
Journal:  Oncogene       Date:  2021-05-04       Impact factor: 9.867

3.  Identification of Meflin as a Potential Marker for Mesenchymal Stromal Cells.

Authors:  Keiko Maeda; Atsushi Enomoto; Akitoshi Hara; Naoya Asai; Takeshi Kobayashi; Asuka Horinouchi; Shoichi Maruyama; Yuichi Ishikawa; Takahiro Nishiyama; Hitoshi Kiyoi; Takuya Kato; Kenju Ando; Liang Weng; Shinji Mii; Masato Asai; Yasuyuki Mizutani; Osamu Watanabe; Yoshiki Hirooka; Hidemi Goto; Masahide Takahashi
Journal:  Sci Rep       Date:  2016-02-29       Impact factor: 4.379

4.  Essential Role of Linx/Islr2 in the Development of the Forebrain Anterior Commissure.

Authors:  Shaniya Abudureyimu; Naoya Asai; Atsushi Enomoto; Liang Weng; Hiroki Kobayashi; Xiaoze Wang; Chen Chen; Shinji Mii; Masahide Takahashi
Journal:  Sci Rep       Date:  2018-05-08       Impact factor: 4.379

5.  The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein-protein interaction in glioblastoma.

Authors:  Virginie Neirinckx; Ann-Christin Hau; Anne Schuster; Sabrina Fritah; Katja Tiemann; Eliane Klein; Petr V Nazarov; André Matagne; Martyna Szpakowska; Max Meyrath; Andy Chevigné; Mirko H H Schmidt; Simone P Niclou
Journal:  Neurooncol Adv       Date:  2019-09-06

6.  Investigation of the association between miR‑181b, Bcl‑2 and LRIG1 in oral verrucous carcinoma.

Authors:  Zhi-Yuan Deng; Yue-Hong Wang; Hong-Zhi Quan; Ou-Sheng Liu; Yi-Ping Li; Yuan Li; Wu Zhu; Krishna Munnee; Zhan-Gui Tang
Journal:  Mol Med Rep       Date:  2016-08-09       Impact factor: 2.952

7.  Analysis of Toll-Like Receptors in Human Milk: Detection of Membrane-Bound and Soluble Forms.

Authors:  Chiara Cattaneo; Alice Caramaschi; Elena Uga; Michela Braghin; Gianluca Cosi; Chiara Peila; Maria C Strozzi; Miriam Sabatini; Diego Gazzolo; Marcello Manfredi; Maria Cavaletto
Journal:  J Immunol Res       Date:  2019-12-04       Impact factor: 4.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.